Could a common vitamin help fight sepsis? new trial aims to find out
NCT ID NCT07655791
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 4 trial tests whether adding nicotinamide (vitamin B3) to standard sepsis care can reduce organ failure and inflammation in ICU patients. Researchers will give 60 adults with sepsis either nicotinamide or a placebo for 7 days, measuring changes in organ function and blood markers. The goal is to see if this safe, inexpensive vitamin can improve outcomes in a life-threatening condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Nicotinamide (vitamin B3) 1000 mg oral tablet
- What this could lead to
- If it works, this could point toward a simple, safe, and cheap vitamin supplement to help control sepsis and reduce organ failure in the ICU.
- What could go wrong
- This is a small, early-stage trial with only 60 patients, so results may not apply broadly. Nicotinamide at high doses can cause side effects like diarrhea or stomach upset.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPSIS - TO REDUCE MORTALITY IN THE INTENSIVE CARE UNIT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
El Demardash Hospital
Cairo, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.